Samsara Biocapital, LLC

In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 14, 2025), Samsara Biocapital, LLC reported 25 stock positions worth $765.9 million. Its top holding was Mineralys Therapeutics (MLYS) at 31.0% of the portfolio, followed by Scholar Rock (SRRK, 27.3%) and Kalaris Therapeutics (KLRS, 8.6%). Compared with Q2 2025, it opened 2 new positions, sold out of 4, added to 2 and reduced 9. The biggest buy was Mineralys Therapeutics (MLYS, shares +10%) and the biggest sale an exit from Cargo Therapeutics (CRGX).

Most Recent 13F
Q2 2026
Location
PALO ALTO, CA
CIK
0001744967
Portfolio Value
$765.9M (Q3 2025)
SEC Filing
0001744967-25-000004 ↗ filed Nov 14, 2025

Holdings Value

0$500.0M$1.0B$1.5B Q1 2024: $646.3M Q1 2024 Q2 2024: $477.8M Q2 2024 Q3 2024: $520.3M Q3 2024 Q4 2024: $728.6M Q4 2024 Q1 2025: $560.8M Q1 2025 Q2 2025: $488.9M Q2 2025 Q3 2025: $765.9M $765.9M Q3 2025 Q4 2025: $969.2M Q4 2025 Q1 2026: $1.0B Q1 2026 Q2 2026: $1.2B Q2 2026

Holdings 25 stocks · $765.9M
MLYS Mineralys Therapeutics Inc. 31.01% 6,263,151 $237.5M Add +10.4%
SRRK Scholar Rock Holding Corp. 27.29% 5,612,896 $209.0M No change
KLRS Kalaris Therapeutics Inc. 8.64% 11,448,081 $66.2M No change
SEPN Septerna Inc. 7.73% 3,149,128 $59.2M No change
NGNE Neurogene Inc. 3.89% 1,717,127 $29.8M No change
ALMS Alumis Inc. 2.50% 4,801,370 $19.2M No change
UPB Upstream Bio Inc. 2.36% 962,154 $18.1M Reduce -33.3%
GOSS Gossamer Bio Inc. 2.11% 6,130,268 $16.1M No change
LENZ Lenz Therapeutics Inc. 2.09% 343,012 $16.0M No change
AQST Aquestive Therapeutics Inc. 1.82% 2,500,000 $14.0M New
PVLA Palvella Therapeutics Inc. 1.72% 209,634 $13.1M Reduce -38.3%
AVDL Avadel Pharmaceuticals Ltd. 1.35% 675,504 $10.3M No change
VTVT VTV Therapeutics Inc. Class A 1.14% 374,461 $8.7M Add +81.1%
NKTX Nkarta Inc. 1.02% 3,768,035 $7.8M No change
CTNM Contineum Therapeutics Inc. Class A 0.88% 571,142 $6.7M Reduce -3.0%
ACLX Arcellx Inc. 0.87% 81,165 $6.7M Reduce -20.0%
ABVX Abivax SA-ADR 0.84% 75,442 $6.4M New
JBIO Jade Biosciences Inc. 0.60% 531,163 $4.6M No change
AURA Aura Biosciences Inc. 0.47% 584,849 $3.6M Reduce -41.5%
ZYME Zymeworks Inc. 0.46% 207,901 $3.6M Reduce -33.0%
SRZN Surrozen Inc. 0.41% 241,400 $3.1M No change
RYTM Rhythm Pharmaceuticals Inc. 0.40% 30,285 $3.1M Reduce -40.0%
STRO Sutro Biopharma Inc. Com SHS 0.25% 2,196,814 $1.9M No change
TERN Terns Pharmaceuticals Inc. 0.13% 135,573 $1.0M Reduce -33.0%
BOLT Bolt Biotherapeutics Inc. 0.03% 48,830 $260K Reduce -6.9%
Other holdings (2): bonds, preferreds, convertibles and warrants · $29K (not counted above)
SecurityClassShares / PrincipalValueChange
NUVB.WS Nuvation Bio Inc. -CW27 *W EXP 02/10/202 133,333$27KNo change
SRZNW Surrozen Inc.-CW25 *W EXP 08/01/203 99,999$2KNo change

Total filed on the 13F, all lines: $765.9M.

Portfolio Sells Q2 2025 → Q3 2025
CRGX Cargo Therapeutics Inc. Sold out 0.00% −3.72
UPB Upstream Bio Inc. Reduce -33.3% 2.36% −0.88
AURA Aura Biosciences Inc. Reduce -41.5% 0.47% −0.81
ACLX Arcellx Inc. Reduce -20.0% 0.87% −0.50
ZYME Zymeworks Inc. Reduce -33.0% 0.46% −0.33
RYTM Rhythm Pharmaceuticals Inc. Reduce -40.0% 0.40% −0.25
TNGX Tango Therapeutics Inc. Sold out 0.00% −0.22
HLVX Hillevax Inc. Sold out 0.00% −0.16
ARTV Artiva Biotherapeutics Inc. Sold out 0.00% −0.09
BOLT Bolt Biotherapeutics Inc. Reduce -6.9% 0.03% −0.03
TERN Terns Pharmaceuticals Inc. Reduce -33.0% 0.13% −0.02
PVLA Palvella Therapeutics Inc. Reduce -38.3% 1.72% +0.15
CTNM Contineum Therapeutics Inc. Class A Reduce -3.0% 0.88% +0.40

Portfolio Buys Q2 2025 → Q3 2025
MLYS Mineralys Therapeutics Inc. Add +10.4% 31.01% +15.30
AQST Aquestive Therapeutics Inc. New 1.82% +1.82
ABVX Abivax SA-ADR New 0.84% +0.84
VTVT VTV Therapeutics Inc. Class A Add +81.1% 1.14% +0.51

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 24$1.2BSRRK, ALMS, MLYS, SEPN, ALMR
Q1 2026 22$1.0BSRRK, MLYS, ALMS, SEPN, KLRS
Q4 2025 20$969.2MSRRK, MLYS, KLRS, SEPN, ALMS
Q3 2025 25$765.9MMLYS, SRRK, KLRS, SEPN, NGNE
Q2 2025 27$488.9MSRRK, MLYS, SEPN, KLRS, NGNE
Q1 2025 35$560.8MSRRK, KLRS, MLYS, NGNE, ALMS
Q4 2024 41$728.6MSRRK, CRGX, SEPN, MLYS, NGNE
Q3 2024 40$520.3MCRGX, MLYS, SRRK, NGNE, ALMS
Q2 2024 38$477.8MCRGX, MLYS, SRRK, NGNE, ACLX
Q1 2024 37$646.3MSRRK, CRGX, MLYS, NGNE, NKTX